Loading...
Loading...
MDWD| Name | Value |
|---|---|
| Revenues | 4,964.0K |
| Cost of Revenue | 4,357.0K |
| Gross Profit | 607.0K |
| Operating Expense | 4,341.0K |
| Operating I/L | -3,734.0K |
| Other Income/Expense | -5,971.0K |
| Interest Income | 0.0K |
| Pretax | -9,705.0K |
| Income Tax Expense | 24.0K |
| Net Income/Loss | -9,729.0K |
MediWound Ltd. is a biopharmaceutical company specializing in the development, manufacturing, and commercialization of innovative bio-therapeutic solutions for tissue repair and regeneration. The company's flagship product, NexoBrid, is marketed for the removal of eschar in adults with deep partial- and full-thickness thermal burns. Additionally, MediWound is advancing EscharEx, which has completed Phase II clinical trials for debridement of chronic and hard-to-heal wounds, and MW005, currently in phase I/II for the treatment of low-risk basal cell carcinoma.
